Additionally, TCGA research has revealed key genomic alterations in colorectal cancer, including frequent mutations in APC, KRAS, and TP53, as well as pathway disruptions in WNT and TGF-β signaling, driving advancements in targeted therapies [440]. This evidence concerns the gene KRAS and colorectal cancer.